Minor groove binders 1998 - 2004

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 12, 2004, Pages 1693-1724

  Suckling, Colin J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Antibacterial agent; Antifungal agent; Antiviral agent; Aryl benzimidazole; Cancer chemotherapy; DNA binding compound; Heterocyclic polyamide; Minor groove; Natural product analogue; Pyrrolobenzodiazepine

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ADOZELESIN; ALKYLATING AGENT; ANTHRAMYCIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTITRYPANOSOMAL AGENT; ANTIVIRUS AGENT; AZIRIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; BIZELESIN; BROSTACILLIN; BROSTALLICIN; CARZELESIN; CONGOCIDINE; CONGOCIDINE DERIVATIVE; DISTAMYCIN A; DISTAMYCIN A DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; ETHYLENE OXIDE DERIVATIVE; FURAN DERIVATIVE; MUSTARD GAS DERIVATIVE; POLYAMIDE; RACHELMYCIN; RACHELMYCIN DERIVATIVE; TALLIMUSTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BINDING AFFINITY; CANCER; CLINICAL TRIAL; DISEASE MODEL; DNA STRUCTURE; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PERITONITIS; PNEUMOCYSTOSIS; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; TUMOR XENOGRAFT;

EID: 10344255623     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.12.1693     Document Type: Review

References (75)

1. REDDY BP, SONDHI SM, LOWN JW: Synthetic DNA minor groove-binding drugs. Pharmacol. Therap. (1999) 84:1-111.
2. ARCAMONE FM, ANIMATI F, BARBIERI B et al.: Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J. Med. Chem. (1989) 32:774-778.
3. FINLAY AC, HOCHSTEIN FA, SOBIN BA et al.: Netropsin, a new antibiotic produced by a Streptomyces. J. Am. Chem. Soc. (1951) 73:341.
4. GREHN L, RAGNARSSON U, ERIKSSON B et al.: Synthesis and antiviral activity of distamycin A analogues: substitutions on the different pyrrole nitrogens and in the amidine function. J. Med. Chem. (1983) 26:1042-1049.
5. SHARMA SK, BILLAUD J-N, TANDON M et al.: Inhibition of feline immunodeficiency virus (FIV) replication by DNA binding polyamides. Bioorg. Med. Chem. Lett. (2002) 12:2007-2010.
6. DICKINSON LA, GULIZIA RJ, TRAUGER JW et al.: Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc. Natl. Acad. Sci. USA (1998) 95 12890-12895.
7. BAILLY C, CHAIRES JB: Sequence specific DNA minor groove binders. Design and synthesis of netropsin and distamycin analogues. Bioconjug. Chem. (1998) 9:513-538.
8. HANKA LJ, DIETZ A, GERPHIEDE SA, et al.: CC-1065 (NSC-298223), a new antitumour antibiotic: production, in vitro biological activity, microbial assays, and taxonomy of producing organisms. J. Antibiot. (1978) 31:1211-1217.
9. LEMGRUBER W, BATCHO AD, SCHENKER F: The structure of anthramycin. J. Am. Chem. Soc. (1965) 87:5793-5795.
10. HARSHMAN ICD, DERVAN PB: Molecular recognition of DNA by Hoechst 33258. Nucleic Acids Res. (1985) 13:4825-4835.
11. UMETSKAIA VN, RZANOV, IM: Mechanism of interaction of DNA with the fluorescent dye, Hoechst 33258. Biofizika (1990) 35 399-401.
12. DAN O, BERGEN G, DERMANT E, et al.: Trypanocide diamidine of 2-phenylbenzofurans, 2-phenylindene and 2-phenylindole. Liebigs Ann. Chem. (1971) 749:68-89.
13. KAYSER K, BAUMGARTNER K, GABIUS HJ: Cytometry with DAPI-stained tumor imprints. Anal. Quant. Cytol. Histol. (1996) 18:115-120.
14. DERVAN PB: Molecular recognition of DNA by small molecules. Bioorg. Med. Chem. (2001) 9:2215-2235.
15. TABERNO L, VERDAGAUER N, COLL M et al.: Molecular structure of the A-tract DNA dodecamer d(CGCAAATTTGCG) complexed with the minor groove binding drug, netropsin. Biochemistry (1993) NN-8403 (Protein Data Bank code 121D).
16. 2. Acta Cryst. D. (1999) 55:602-609 (Protein Data Bank code 378D).
17. TSE WC, TAKAHIRO I, BOGER DL: Comprehensive high-resolution analysis of hairpin polyamides utilizing a fluorescent intercalator displacement (FID) assay. Bioorg. Med. Chem. (2003) 11: 4479-4486.
18. ANTHONY N, MACKAY SP, WAIGH RD et al.: A highly predictive model of ligand binding to the minor groove of DNA. Submitted.
19. 2. Nucleic Acids Res. (2000) 28:728
20. TRAUGER JW, BAIRD EE, DERVAN PB: Recognition of DNA by designed ligands at subnanomolar concentrations. Nature (1996) 382:559-561.
21. GEIERSTANGER BH, MRKSICH M, DERVAN PB et al.: Design of a G.C specific DNA minor groove binder. Science (1994) 266 646-650.
22. SHARMA SK, TANDON M, LOWN JW: Design and synthesis of new thiazolated cross-linked DNA binding polyamides for altered sequence recognition. Tetrahedron (2002) 58:3417-3421.
23. BUGREEV DV, VASYUTINA EL, RYABININ VA et al.: Inhibition of human DNA topoisomerase I by new DNA minor groove ligands: derivatives of oligo-1,3-thiazolocarboxamides. Antisense Nucleic Acid Drug Dev. (2001) 11:137-147.
24. PLOUVIER, B, HOUSSIN R, HECQUET B et al.: Antitumour combilexin, a thiazole containing analogue of netropsin linked to an acridine chromophore. Bioconjug. Chem. (1994) 5:475-481
25. URBACH AR, SZEWCZYK JW, WHITE S et al.: Sequence selectivity of 3-hydroxypyrrole/pyrrole ring pairings in the DNA minor groove. J. Am. Chem. Soc. (1999) 121:11621-11629.
26. ELLERVIK U, WANG CC, DERVAN PB: Hydroxybenzamide/pyrrole pair distinguishes T.A from A.T base pairs in the minor groove of DNA. J. Am. Chem. Soc. (2000) 122:9354-9360.
27. BUERLI RW, GE Y, WHITE S et al.: DNA binding ligands with excellent antibiotic potency against drug-resistant Gram-positive bacteria. Bioorg. Med. Chem. Lett. (2002) 12:2591-2594
28. SOLA F, FARAO M, PESENTI E et al.: Antitumour activity of FCE 26644, a new growth factor complexing molecule. Cancer Chemother. Pharmacol. (1995) 36:217-222.
29. CLANTON DJ, BUCKHEIT RW JR TERPENING SJ et al.: Novel sulfonated and phosphonated analogues of distamycin which inhibit the replication of HIV. Antiviral Res. (1995) 27:335-354.
30. SATZ AL, BRUICE TC: Recognition in the minor groove of double stranded DNA by microgonotropens. Accts. Chem. Res. (2002) 35 86-95.
31. GOTTESFELD JM, MELANDER C, SUTO RK et al. Sequence-specific recognition of DNA in the nucleosome by pyrrole-imidazole polyamides. J. Mol. Biol. (2001) 309 615-629.
32. DUDOUET B, BURNETT R, DICKINSON LA et al.: Accessibility of nuclear chromatin by DNA binding polyamides. Chem. Biol. (2003) 10:859-867.
33. CROWLEY KS, PHILLION DP: WOODARD SS et al.: Controlling the intracellular localisation of fluorescent polyamide analogues in cultured cells. Bioorg. Med. Chem. Lett. (2003) 13:1565-1570.
34. SHARMA SK, MORRISSEY AT, MILLER GG et al.: Design, synthesis, and intracellular localisation of a fluorescently labeled DNA binding polyamide related to the antibiotic distamycin. Bioorg. Med. Chem. Lett. (2001) 11:769-772.
35. MAESHIMA K, JANSSEN S, LAEMMLI UK: Specific targeting of insect and vertebrate telomeres with pyrrole and imidazole polyamides. EMBO J. (2001) 20:3218-3228.
36. 1H NMR studies. J. Biomol. Struct. Dyn. (1990) 8:331-357.
37. SINGH MP, JOSEPH T, KUMAR S et al.: Synthesis and sequence specific DNA binding of a topoisomerase inhibitory analogue of Hoechst 33258 designed for altered base and sequence recognition. Chem. Res. Toxicol. (1992) 5:597-507.
38. BARCELLONA ML, GRATTON E: The fluorescence properties of a DNA probe, 4′,6-diamidino-2-phenylindole complex. Biochim. Biophys. Acta (1990) 993:174-178.
39. JANSEN K, LINCOLN P, NORDEN B: Binding of DAPI analogue 2,5-bis(4-amidinophenyl)furan to DNA. Biochemistry (1993) 32 6605-6612.
40. 2. J. Med. Chem. (1996) 39:4554-4562.
41. ANTHONY NG, FOX KR, JOHNSTON F et al.: DNA binding of a short lexitropsin. Bioorg. Med. Chem. Lett. (2004) 14 1353-1356.
42. SUCKLING CJ: The cyclopropyl group in studies of enzyme mechanism and inhibition. Angew. Chem. Int. Edn. Engl. (1988) 27 537-552.
43. BOGER DL, JOHNSON DS, YUN W et al.: Molecular basis for sequence selective alkylation of DNA by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT rich adenine N3 selectivity. Bioorg. Med. Chem. (1994) 2 115-135.
44. PIERCE JR, ZAZIMIEC M, TANG TS: Comparison of sequence preference of tomamycin and anthramycin - DNA bonding by exonuclease III and λ exonuclease digestion and UVrABC nuclease incision analysis. Biochemistry (1993) 32:7069-7078.
45. KHALAF AI, PITT AR, SCOBIE M et al.: The synthesis of some head to head linked DNA minor groove binders. Tetrahedron (2000) 56: 5225-5239.
46. KHALAF AI, PITT AR, SCOBIE M et al.: Synthesis of novel DNA binding agents: indole-containing analogues of bis netropsin. J. Chem. Res. (2000) 264-265.
47. KHALAF AI, EBRAHIMABADI AR, DRUMMOND AL et al.: Synthesis and antimicrobial activity of some netropsin analogues. Org. Biomol. Chem. in press.
48. DYATKINA NB, ROBERTS CD, KEICHER JD, et al.: Minor groove binders as antibacterial agents. 1. Pyrrole tetraamides are potent antibacterial agents against vancomycin resistant Enterococci and methicillin resistant Staphyllococcus aureus. J. Med. Chem. (2002) 45:805-817.
49. KHALAF AI, WAIGH RD, DRUMMOND AJ et al.: Distamycin analogues with enhanced lipophilicity. J. Med. Chem. (2004) 47 2133-2156.
50. JAMES PL, MERKINA E, KHALAF AI, et al.: DNA sequence recognition by an isopropyl substituted thiazole polyaamide: Nucleic Acid. Res. (2004) 32:3410-3417.
51. PARKINSON JA, KHALAF AI, MACKAY SP et al.: NMR studies of a short lexitropsin: DNA minor groove binding complex: sequence specificity for 5′HACTAGT-3′. J. Am. Chem. Soc. Doi=10.1021/ja030658n.
52. KHALAF AI, PITT AR, SCOBIE M et al.: DNA binding, solubility, and partitioning characteristics of extended lexitropsins. J. Med. Chem. (2000) 43:3257-3266.
53. BROYLES S, KREMER M, KNUTSON BA: Antiviral activity of distamycin A against vaccinia virus is the result of inhibition of postreplicative mRNA synthesis. J. Virol. (2004) 78 2137-2141.
54. COZZI P: The discovery of a new potential anticancer drug: a case history. Il Farmaco (2003) 58:213-220.
55. TEN TIJE AJ, VERWEIJ J, SPARREBOOM A et al.: Phase I and pharmacokinetic study of brostacillin (PNU-166196), a new DNA minor groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer. Clin. Cancer Res. (2003) 9:2957-2964.
56. FEDIER A, FOWST C, TURSI J et al.: Brostacillin (PNU-166196) - a new DNA minor groove binder retains sensitivity in DNA mismatch repair-deficient tumour cells. Br. J. Cancer (2003) 89 1559-1565.
57. FOSTER BJ, DEKNONING TF, KELLY R et al.: Phase I trial of adozelesin using the treatment schedule of daily × 5 every three weeks. Invest. New Drugs (1996) 13:321-326.
58. FLEMING GF, RATAIN MJ, O'BRIEN SM, et al.: Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J. Natl. Cancer Inst. (1994) 86:368-372.
59. CARTER CA, WAUD WR, LI LH et al.: Preclinical antitumour activity of bizelesin in mice. Clin. Caner Res. (1996) 2:1143-1149.
60. SCHWARTZ GH, PATNAIK A, HAMMOND LA et al.: A Phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann. Oncol. (2003) 14:775-782.
61. ALBERTS SR, ERLICHMAN C, REID JM et al.: Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Cancer Res. (1998) 4:2111-2117.
62. CAO P-R, MCHUGH MM, MELENDY T et al.: The DNA minor groove alkylating cyclopropylpyrroloindole drugs adozelesin and bizelesin induce different DNA damage response pathways in human colon carcinoma HCT116 cells. Mol. Cancer Therap. (2003) 2:651-659.
63. GREGSON SJ, HOWARD PW, CORCORAN KE et al.: Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. Bioorg. Med. Chem. Lett. (2000) 10:1845-1847.
64. GREGSON SJ, HOWARD PW, BARCELLA S et al.: Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. Bioorg. Med. Chem. Lett. (2000) 10:1849-1851.
65. GREGSON SJ, HOWARD PW, HARTLEY JA et al. DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J. Med. Chem. (2001) 44:737-748.
66. SMELLIE M, BOSE DS, THOMPSON AS et al.: Sequence selective recognition of DNA duplex through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine (PBD) dimers. Biochemistry (2003) 8232-8239.
67. WILLIAMS GP, TAYLOR JP, SHNYDER S et al.: Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence selective pyrrolobenzodiazepine (PBD) dimer DNA cross-linking agent. Investig. New Drugs (2004) 22:231-240.
68. GREGSON SJ, HOWARD PW, GULLICK DR et al.: Linker length modulates DNA cross-linking reactivity and cytotoxicity of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimers. J. Med. Chem. (2004) 47:1161-1174.
69. HARTLEY JA, SPANSWICK VJ, BROOKS N et al.: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res. in press.
70. ALLEY MC, HOLLINGSHEAD MG, PACULA-COX CM et al.: SJG-136 (NSC 694501) A novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity. Part 2: efficacy evaluations. Cancer Res. in press.
71. PEPPER CJ, HAMBLY RM, FEGAN CD, THURSTON DE: The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-CLL cells with evidence of a p53-independent mechanism of cell kill. Cancer Res. in press.
72. RUCKER VC, FOISTER S, MELANDER C et al.: Sequence specific fluorescence detection of double strand DNA. J. Am. Chem. Soc. (2003) 125:1195-1202.
73. BUERLI RW, MCMINN D, KAIZERMAN JA et al.: DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives. Bioorg. Med. Chem. Lett. (2004) 14 1253-1257;
74. BUERLI RW, JONES P, MCMINN D, et al.: DNA binding ligands targeting drug resistant Gram-positive bacteria. Part 2: C-terminal benzimadazoles and derivatives. Bioorg. Med. Chem. Lett. (2004) 14:1259-1263.
75. BUERLI RW, KAIZERMAN JA, DUAN J-X et al.: DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids. Bioorg. Med. Chem. Lett. (2004) 14:2067-2072.